OBJECTIVES Many countries have authorized the emergency use of oral antiviral agents for
patients with mild-to-moderate cases of coronavirus disease 2019 (COVID-19). We …

Background Nirmatrelvir-ritonavir is highly effective in preventing severe coronavirus
disease 2019 (COVID-19) in high-risk patients with mild-to-moderate severity. However, real …

Background In this study, we aimed to compare the effectiveness and adverse reactions of
nirmatrelvir/ritonavir and molnupiravir in high-risk outpatients with coronavirus disease 2019 …

Background Real-world data is currently limited on the association between oral antiviral
therapy and healthcare system burden in patients with mild-to-moderate COVID-19. This …

Background Nirmatrelvir/ritonavir was Korea's first oral antiviral agent to treat coronavirus
disease 2019 (COVID-19). We analyzed the nirmatrelvir/ritonavir prescription rate and …

Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …

A clear understanding of real-world uptake of nirmatrelvir–ritonavir for treatment of SARS-
CoV-2 can inform treatment allocation strategies and improve interpretation of effectiveness …

Background and aims Coronavirus disease 2019 (COVID-19) imposes a substantial and
ongoing burden on the US healthcare system and society. Molnupiravir is a new oral …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

Several randomized controlled trials and real‐world cohort studies have demonstrated the
efficacies of nirmatrelvir plus ritonavir (NMV‐r) and molnupiravir (MOV) in at‐risk patients …